Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis

Greg M. Thaera, Dean Marko Wingerchuk, Jonathan L. Carter

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. Background Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The enhanced conduction along demyelinated axons promoted by dalfampridine could potentially lead to development of positive neurologic phenomena. Methods We reviewed the medical records of patients who were started on dalfampridine for activation of positive sensory or motor symptoms. Results Four of 76 patients (5.3%) developed positive sensory symptoms within one month of starting dalfampridine; one additional patient had new-onset seizure. Cessation of dalfampridine was insufficient to resolve symptoms in two patients with recurrent trigeminal neuralgia. Conclusions Initiation of dalfampridine may be associated with initiation or recurrence of positive sensory symptoms in patients with multiple sclerosis. The increased axonal conduction from potassium channel blockade may contribute to this exacerbation of positive sensory phenomena.

Original languageEnglish (US)
Pages (from-to)107-109
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume3
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Nervous System
Multiple Sclerosis
Potassium Channel Blockers
4-Aminopyridine
Trigeminal Neuralgia
Potassium Channels
Gait
Medical Records
Axons
Seizures
Recurrence

Keywords

  • Dalfampridine
  • Multiple sclerosis
  • Paroxysmal neurologic symptoms
  • Seizures
  • Sensation disorders
  • Trigeminal neuralgia

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis. / Thaera, Greg M.; Wingerchuk, Dean Marko; Carter, Jonathan L.

In: Multiple Sclerosis and Related Disorders, Vol. 3, No. 1, 01.2014, p. 107-109.

Research output: Contribution to journalArticle

@article{a9cab88e290f422c848d023c194ce912,
title = "Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis",
abstract = "Objective Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. Background Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The enhanced conduction along demyelinated axons promoted by dalfampridine could potentially lead to development of positive neurologic phenomena. Methods We reviewed the medical records of patients who were started on dalfampridine for activation of positive sensory or motor symptoms. Results Four of 76 patients (5.3{\%}) developed positive sensory symptoms within one month of starting dalfampridine; one additional patient had new-onset seizure. Cessation of dalfampridine was insufficient to resolve symptoms in two patients with recurrent trigeminal neuralgia. Conclusions Initiation of dalfampridine may be associated with initiation or recurrence of positive sensory symptoms in patients with multiple sclerosis. The increased axonal conduction from potassium channel blockade may contribute to this exacerbation of positive sensory phenomena.",
keywords = "Dalfampridine, Multiple sclerosis, Paroxysmal neurologic symptoms, Seizures, Sensation disorders, Trigeminal neuralgia",
author = "Thaera, {Greg M.} and Wingerchuk, {Dean Marko} and Carter, {Jonathan L.}",
year = "2014",
month = "1",
doi = "10.1016/j.msard.2013.05.003",
language = "English (US)",
volume = "3",
pages = "107--109",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis

AU - Thaera, Greg M.

AU - Wingerchuk, Dean Marko

AU - Carter, Jonathan L.

PY - 2014/1

Y1 - 2014/1

N2 - Objective Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. Background Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The enhanced conduction along demyelinated axons promoted by dalfampridine could potentially lead to development of positive neurologic phenomena. Methods We reviewed the medical records of patients who were started on dalfampridine for activation of positive sensory or motor symptoms. Results Four of 76 patients (5.3%) developed positive sensory symptoms within one month of starting dalfampridine; one additional patient had new-onset seizure. Cessation of dalfampridine was insufficient to resolve symptoms in two patients with recurrent trigeminal neuralgia. Conclusions Initiation of dalfampridine may be associated with initiation or recurrence of positive sensory symptoms in patients with multiple sclerosis. The increased axonal conduction from potassium channel blockade may contribute to this exacerbation of positive sensory phenomena.

AB - Objective Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. Background Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The enhanced conduction along demyelinated axons promoted by dalfampridine could potentially lead to development of positive neurologic phenomena. Methods We reviewed the medical records of patients who were started on dalfampridine for activation of positive sensory or motor symptoms. Results Four of 76 patients (5.3%) developed positive sensory symptoms within one month of starting dalfampridine; one additional patient had new-onset seizure. Cessation of dalfampridine was insufficient to resolve symptoms in two patients with recurrent trigeminal neuralgia. Conclusions Initiation of dalfampridine may be associated with initiation or recurrence of positive sensory symptoms in patients with multiple sclerosis. The increased axonal conduction from potassium channel blockade may contribute to this exacerbation of positive sensory phenomena.

KW - Dalfampridine

KW - Multiple sclerosis

KW - Paroxysmal neurologic symptoms

KW - Seizures

KW - Sensation disorders

KW - Trigeminal neuralgia

UR - http://www.scopus.com/inward/record.url?scp=84884283213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884283213&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2013.05.003

DO - 10.1016/j.msard.2013.05.003

M3 - Article

AN - SCOPUS:84884283213

VL - 3

SP - 107

EP - 109

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

IS - 1

ER -